Aeon biopharma presents positive clinical and pre-clinical data for abp-450 (prabotulinumtoxina) in treating cervical dystonia and ptsd, respectively, at a leading neurotoxin conference

– open label extension (ole) phase 2 data show peak efficacy for all abp-450 doses and cycles in treating cervical dystonia (cd) occurred early, within 4 weeks; durability of effect was demonstrated 12 to 16 weeks post treatment –

AEON Ratings Summary

AEON Quant Ranking